

Pathology of hematolymphoid system

Acute Leukemia

Histiocytic tumors

Professor Tariq Aladily
Department of Pathology
The University of Jordan
tnaladily@ju.edu.jo



School of Medicine





* Most of disorders related to WBCs are neoplastic.

ACUTE MYELOID LEUKEMIA AML

Most aggressive

For diagnosis we depend on:

- Morphology
- Examine the antigens
- Karyotype: Chromosomes

- Occur at all age groups, but more common in elderly

→ Many Subtypes
[?] Heterogenous, diagnosis is made by morphologic, immunophenotypic and karyotype studies

* Some mutations are common

[?] Prognosis depends most importantly on type of mutations (molecular and cytogenetic studies)
↳ Chromosomes
↳ Karyotype

[?] Symptoms are accelerated, become significant within few weeks → cytopenia because the bone marrow is filled with blasts instead of normal cells

[?] Symptoms are related to anemia, thrombocytopenia and neutropenia

[?] Involvement of LN, spleen and solid organs is rare. When occurs, it is called myeloid sarcoma (acute monoblastic leukemia)
↳ Solid mass → destruction
So they remain in the bone marrow or in the peripheral blood



PATHOGENESIS

- Mutations in genes of transcription factors required for maturation and differentiation of myeloblasts

↳ So they do not mature

- Additional mutations in tyrosine kinase pathways (RAS)

- Epigenetic mutation is common (20%); mutation is isocitrate dehydrogenase (IDH) produces an oncometabolite that blocks enzyme of epigenome and interferes with myeloblast differentiation



← responsible for all the epigenetic mutations in all the DNA.



WHO-CLASSIFICATION OF AML

- *usually very poor prognosis*
Therapy related AML: occurs after treatment with chemo or radiotherapy *It's toxic to the stem cells*
- AML with recurrent cytogenetic mutation
↳ They are named according to the mutation. Just an ex. AML with Ch7 inversion
- AML with myelodysplasia: occurs de novo or complicates MDS → AML with MDS
myelodysplastic syndrome
- AML-Not otherwise specified
- Diagnosis of AML: 20% blasts in peripheral blood or bone marrow (of nucleated cells)
They are rare cells → IF the MD is 20% of the total cells either in blood or marrow it becomes AML.
IF less than 20% it's still in the MDS stage.





- Morphology: large cells, high N/C ration, fine granules in cytoplasm, fine chromatin, prominent nucleoli
large Nucleus
- ↳ normal mature
- Auer rods: small pink rods present in cytoplasm, represent peroxidase enzyme
contain many enzymes mainly myeloperoxidase
immature
- ↳ Only seen in myeloblasts they are granules but with morphologic change (same content).
- Myeloblasts express CD34, myeloperoxidase (MPO), CD13, CD33
- Sometimes: monoblast, erythroblast, megakaryoblast
↳ If it reaches >20%

* CD4: only expressed in blasts and it's negative in mature cells.

* We use the flowcytometry to check the presence of these antigens.



OUTCOME

- Generally ^{very poor prognosis} poor, <30% responds to chemotherapy *There are new therapies but still promising like Isocitrate dehydrogenase Inhibitors.*
- Worse than ALL
- P53 mutation: worse outcome
- IDH inhibitors are new promising drugs



SubType of AML

ACUTE PROMYELOCYTIC LEUKEMIA

- Promyelocyte is the stage of maturation that comes after myeloblast.
- we don't find blasts → we find malignant promyelocyte.
- Also called AML-M3
 - ↳ They were designated by numbers
- Maturation is arrested at promyelocyte stage
- Leukemic cells appear similar to promyelocytes (heavy cytoplasmic granules, numerous Auer rods, negative for CD34) positive only in blasts.
- Carry recurrent mutation: $t(15;17)$ fusion between PML gene (chrom 15) with alpha retinoic acid receptor (RARA) on chrom 17. special mutations that are not seen in any other leukemia
Chimeric fusion gene produces a promyelocyte protein that blocks promyelocyte maturation by inhibiting the action of retinoic acid.
- All trans-retinoic acid (ATRA), a vitamin A analogue, overcomes this block. Effect is synergistic with arsenic trioxide (degrades oncoprotein)
- Malignant promyelocyte secrete tissue factor, causing DIC
 - * Vitamin A is important for the maturation of leukemic cells.
 - * The mutation leads to the appearance of a chimeric protein that inhibits the usage of VIT.A for maturation.
 - * Treatment: Very large dose of VIT.A → force the chimeric protein to detach from the receptor (RARA).
 - * VIT.A that's used is alpha trans retinoic acid → which is a derivative with the same function.



* other treatment is Arsenic trioxide : toxic was previously used as poison.


* No Chemotherapy ^{2nd}

* patients develop DIC . because the promyelocyte secrete TF. And patients die from DIC not from the cancer itself.

* They are like the blasts but with numerous granules.

* Auer Rods .

* May find 2 nuclei because it's malignant.



- APL: malignant promyelocytes show numerous cytoplasmic granules and Auer rods. The nuclei are commonly cleaved.



PRECURSOR B AND T CELL NEOPLASMS

☆ Can appear in blood and bone marrow, and can appear in other tissues.

☆ Lymphocytes are everywhere.

☆ When it arises in tissues it's known as lymphoblastic lymphoma (lymphoma).

- Lymphoblastic lymphoma when occurs in solid tissue (T>B)
- Acute lymphoblastic leukemia when circulates peripheral blood and involve bone marrow (B>T)
- B-ALL is the most common childhood malignancy
 - ↳ Can occur at any age
- Neoplastic cells are lymphoblasts, the most immature lymphoid cell. Aggressive neoplasms, express CD34 and TDT To distinguish lymphoblasts from leukoblasts.
- T-ALL is less common, presents in adolescents, involving thymus, more common in boys
- B-ALL tends to disseminate to solid organs (brain, testis, spleen)




PATHOGENESIS

- Mutations in transcription factors for genes responsible for maturation of blasts
- In B-LL, mutation in PAX5 gene
- Mutations in RAS signaling and tyrosine kinase proteins promoting cell survival
- Most childhood B-ALL have hyperdiploidy (>50 chromosomes) and t(12;21), involving ETV6 and TUNX1 genes, creating new transcription factor
Single cell with very large number of chromosomes → It's a good prognosis
- Adult B-ALL exhibits t(9;22) between ABL and BCR genes, similar to chronic myeloid leukemia, creating a new tyrosine kinase protein (imatinib)
first mutation treated by targeted therapy
Philadelphia chromosome was discovered firstly in Chronic myeloid leukemia. CML
- T-ALL shows mutation in NOTCH1 gene (70% of cases), PTEN gene (tumor suppressor) and CDKN2A (promotes cell cycle)




MORPHOLOGY OF ALL

- Blasts are large, high N/C ratio
- Chromatin is open (pale)
- Nucleolus sometimes present
- Cytoplasm is not granular



Immunophenotype

B-cell marker



Flow cytometry



lymphoblasts

CLINICAL FEATURES

- Anemia, thrombocytopenia
- Bone pain *Common → fill with H₂O₂*
- Lymphadenopathy and hepatosplenomegaly
- Testicular enlargement
- Mediastinal mass (T-ALL)
↳ In thymus → compression on heart and lungs
- CNS involvement *harder treatment, chemotherapy in the spinal cord*
- Damage to solid organs secondary to leukemic infiltration
↳ like brain
- Favorable prognostic factors in B-ALL: hyperdiploidy, low WBC count, age between 2-10 years
↳ better than ALL
↳ good prognosis
↳ they response to chemo.
- Poor prognostic factors in B-ALL: age < 2 years, age in adolescents or adults, WBC count > 100k



- ★ There are many types of histiocytic tumors.
- ★ This is the most common ↓

LANGERHANS CELL HISTIOCYTOSIS

- Neoplasm of dendritic cells

- APC. They are similar to dendrites in nerves. in case of the disease → they become long and swollen like histiocytes.
- Langerhans cells express CD1a and Langerin

- Langerin is a transmembrane protein, attached to Birbeck granules (tennis racket shape under electron microscope)
- cytotoxic and*
- years before they used to use the EM for diagnosis. Now we directly use antigens.*

- Proliferating Langerhans cells appear large and vacuolated, similar to macrophages

- They become neoplastic → that's why their shapes have changed.
 - Pathogenesis: acquired mutation in serin/threonine kinase BRAF, leads to hyperactivity of this kinase
- Seen in ① B-cell lymphoma ② LCH.*



MULTISYSTEMIC LCH

↳ everywhere in the body

- Occurs mostly in children less than 2 years
- Multiple cutaneous lesion, composed of LCs
- Hepatosplenomegaly and lymphadenopathy
- Pulmonary lesions *Can also affect the heart*
- Osteolytic lesions
- Extensive bone marrow infiltration leads to pancytopenia
- Treated with chemotherapy



UNISYSTEM LCH

- AKA eosinophilic granuloma *other name used in medicine*
or miss name
- Affects a single organ, most commonly bone, then skin, lung, stomach
- Can be unifocal or multifocal
- Unifocal is commonly asymptomatic, can cause pain
- Multifocal unisystem disease presents in children, commonly affects calvaria bone, extends to pituitary gland causing diabetes insipidus, exophthalmos (Hand- Schuller-Christian triad). *Base of the skull*
- Proliferating LCs are admixed with numerous eosinophils, lymphocytes, plasma cells and neutrophils *Bushing of the orbit*
- Treatment: unifocal: surgical excision, multifocal: chemotherapy, sometimes spontaneous regression *they all participate in the mass formation*

